{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Continuous+Dose&page=74",
    "query": {
      "intervention": "Continuous Dose",
      "page": 74
    },
    "page_size": 10
  },
  "pagination": {
    "page": 74,
    "page_size": 10,
    "total_count": 5325,
    "total_pages": 533,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Continuous+Dose&page=75&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Continuous+Dose&page=73&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-12T04:41:59.503Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02227667",
      "title": "Evaluate the Efficacy of MEDI4736 in Immunological Subsets of Advanced Colorectal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "MEDI4736",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2014-12-02",
      "completion_date": "2020-06-29",
      "has_results": true,
      "last_update_posted_date": "2021-06-18",
      "last_synced_at": "2026-11-12T04:41:59.503Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02227667"
    },
    {
      "nct_id": "NCT00440466",
      "title": "PROCRIT Extended Dosing For Maintenance of Hemoglobin in Pre-Dialysis CKD Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Anemia",
        "Renal Diseases"
      ],
      "interventions": [
        {
          "name": "epoetin alfa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 430,
      "start_date": "2007-07",
      "completion_date": "2009-03",
      "has_results": true,
      "last_update_posted_date": "2014-04-21",
      "last_synced_at": "2026-11-12T04:41:59.503Z",
      "location_count": 66,
      "location_summary": "Chula Vista, California • Fountain Valley, California • Los Angeles, California + 63 more",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Lynwood",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00440466"
    },
    {
      "nct_id": "NCT02000401",
      "title": "Intranasal Ketorolac Tromethamine (Sprix) for Acute Pain of Interstitial Cystitis Flare of Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Interstitial Cystitis"
      ],
      "interventions": [
        {
          "name": "Ketorolac Tromethamine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Citrus Valley Medical Research, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 64 Years · Female only"
      },
      "enrollment_count": 15,
      "start_date": "2012-05",
      "completion_date": "2013-07",
      "has_results": false,
      "last_update_posted_date": "2013-12-04",
      "last_synced_at": "2026-11-12T04:41:59.503Z",
      "location_count": 1,
      "location_summary": "Glendora, California",
      "locations": [
        {
          "city": "Glendora",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02000401"
    },
    {
      "nct_id": "NCT01040819",
      "title": "Does Pioglitazone Increase the Production of 15-EPI-Lipoxin A4?",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 2 Diabetes Mellitus"
      ],
      "interventions": [
        {
          "name": "Pioglitazone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2010-02",
      "completion_date": "2011-12",
      "has_results": true,
      "last_update_posted_date": "2016-06-22",
      "last_synced_at": "2026-11-12T04:41:59.503Z",
      "location_count": 2,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01040819"
    },
    {
      "nct_id": "NCT01209845",
      "title": "Ketamine for Low Mood States in the ER",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Depression",
        "Suicide Ideation"
      ],
      "interventions": [
        {
          "name": "ketamine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2010-04",
      "completion_date": "2010-12",
      "has_results": false,
      "last_update_posted_date": "2020-08-24",
      "last_synced_at": "2026-11-12T04:41:59.503Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01209845"
    },
    {
      "nct_id": "NCT03356457",
      "title": "Development of Agents to Diminish the Risk of Hypoglycemia-induced Brain Injury in Type 1 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Hyperglycaemia (Diabetic)"
      ],
      "interventions": [
        {
          "name": "Dichloroacetate",
          "type": "DRUG"
        },
        {
          "name": "Placebo oral capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 21,
      "start_date": "2017-11-30",
      "completion_date": "2019-03-20",
      "has_results": false,
      "last_update_posted_date": "2021-01-22",
      "last_synced_at": "2026-11-12T04:41:59.503Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03356457"
    },
    {
      "nct_id": "NCT05372419",
      "title": "A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Atopic Dermatitis"
      ],
      "interventions": [
        {
          "name": "Lebrikizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "2023-01-12",
      "completion_date": "2025-02-17",
      "has_results": true,
      "last_update_posted_date": "2026-03-09",
      "last_synced_at": "2026-11-12T04:41:59.503Z",
      "location_count": 36,
      "location_summary": "Birmingham, Alabama • Fountain Valley, California • Fremont, California + 30 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fountain Valley",
          "state": "California"
        },
        {
          "city": "Fremont",
          "state": "California"
        },
        {
          "city": "Inglewood",
          "state": "California"
        },
        {
          "city": "Laguna Niguel",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05372419"
    },
    {
      "nct_id": "NCT01247922",
      "title": "Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ependymoma"
      ],
      "interventions": [
        {
          "name": "Erlotinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "OSI Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "1 Year to 21 Years"
      },
      "enrollment_count": 4,
      "start_date": "2011-05-23",
      "completion_date": "2012-09-13",
      "has_results": true,
      "last_update_posted_date": "2024-12-06",
      "last_synced_at": "2026-11-12T04:41:59.503Z",
      "location_count": 11,
      "location_summary": "Birmingham, Alabama • Orange, California • Palo Alto, California + 8 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01247922"
    },
    {
      "nct_id": "NCT00396331",
      "title": "AMD3100 (Plerixafor) With G-CSF in Poor Mobilizing Adult Patients Who Previously Failed Hematopoietic Stem Cell (HSC) Collection/Attempts",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Autologous Stem Cell Transplantation"
      ],
      "interventions": [
        {
          "name": "G-CSF plus plerixafor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genzyme, a Sanofi Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "78 Years",
        "sex": "ALL",
        "summary": "18 Years to 78 Years"
      },
      "enrollment_count": 100,
      "start_date": "2005-10",
      "completion_date": "2009-12",
      "has_results": true,
      "last_update_posted_date": "2014-03-13",
      "last_synced_at": "2026-11-12T04:41:59.503Z",
      "location_count": 8,
      "location_summary": "Duarte, California • Tampa, Florida • Atlanta, Georgia + 5 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Jackson",
          "state": "Mississippi"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00396331"
    },
    {
      "nct_id": "NCT03339401",
      "title": "The AdAPT Trial; Adenovirus After Allogeneic Pediatric Transplantation",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adenovirus"
      ],
      "interventions": [
        {
          "name": "Standard of Care",
          "type": "OTHER"
        },
        {
          "name": "Brincidofovir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Jazz Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Months",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "2 Months to 25 Years"
      },
      "enrollment_count": 29,
      "start_date": "2017-12-22",
      "completion_date": "2019-05-10",
      "has_results": true,
      "last_update_posted_date": "2021-01-25",
      "last_synced_at": "2026-11-12T04:41:59.503Z",
      "location_count": 11,
      "location_summary": "Los Angeles, California • San Francisco, California • Chicago, Illinois + 8 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03339401"
    }
  ]
}